Help get your HCC patients to transplant
TheraSphere™ Y-90 Glass Microspheres is the market leader and first FDA approved transarterial radiation therapy for hepatocellular carcinoma (HCC), delivering targeted damage to the tumor, sparing healthy tissue, and preserving treatment options.
TheraSphere is an efficient and powerful therapy for HCC that safely delivers high-dose radiation which can:
- Aid in achieving surgical candidacy
- Preserve liver transplant eligibility
- Support strong Overall Survival (OS) outcomes
Y-90 is the most utilized LRT bridging strategy for liver transplant candidates with HCC in the US¹
Analysis of data from the Organ Procurement and Transplant Network (OPTN) reflects the increasing adoption by many transplant centers of transarterial radioembolization (TARE) as the primary LRT option surpassing both chemoembolization and thermal ablation.¹
Y-90 patients are more likely to maintain transplant eligibility
A study of 5,677 liver transplant patients (UNOS OPTN data, May 2019 - October 2024) reveals a major advantage for those treated with Y-90.
Fewer treatments needed:
- 80% of Y‑90 patients required only one LRT
- Compared to 56% of TACE patients who required multiple treatments
More streamlined path to transplant:
- Y‑90 reduced the need for repeat procedures²
Lower waitlist dropout risk:
- Patients treated with Y‑90 experienced a 22% lower risk of waitlist dropout vs. TACE²
Y-90 as the leading bridge to transplant
Join Dr. Riad Salem, Dr. Parissa Tabrizian, and Dr. Neil Mehta as they discuss Y‑90 as the #1 locoregional therapy for bridging to transplant, examining real‑world adoption trends and underlying clinical rationale.
Bridging and Downstaging
TheraSphere provides a strong local tumor response and has been studied in patients intended to downstage tumors for transplant or bridge within Milan criteria.
